IND application for HLX3902 approved in China for treatment of metastatic CRPC and solid tumors
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its second innovative T cell engager (TCE), HLX3902—a tri-specific antibody targeting STEAP1×CD3×CD28 developed on the company’s proprietary immune cell engager platform, has been approved by the National Medical Products Administration (NMPA), for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumours. Recently, it has also received clinical trial authorization in Australia. To accelerate the evaluation of HLX3902’s preliminary efficacy and safety in humans, the company plans to initiate multi-regional clinical trials (MRCT) simultaneously in China, Australia, and other regions to evaluate HLX3902’s safety, tolerability, and preliminary efficacy in patients with advanced solid tumours，including prostate cancer.
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a